← Leaderboards
Peter T Nelson
University Of Kentucky
$21,085,191
Attributed
$29,744,396
Total exposure
23
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,744,396 · 23
By mechanism
R01$10,045,438 · 6
RF1$4,893,504 · 2
U24$4,861,895 · 1
P01$4,093,457 · 4
P30$2,733,342 · 2
R21$1,586,248 · 4
Top collaborators
- Gregory A Jicha9 shared
- Cody Bumgardner2 shared
- Matthew Daniel Cykowski2 shared
- Margaret E Flanagan2 shared
- David William Fardo1 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Gregory A Jicha$17,898,620
- Christopher Mark Norris$15,768,108
- Lincoln Shade$142,677
- David William Fardo$3,883,325
- Eseosa T. Ighodaro$73,029
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBrainS DiseaseDementiaPathologyNeuropathologyAutopsyProteinsSamplingProtein Tdp-43Biological MarkersImpaired CognitionCohortTau ProteinsNeurofibrillary TanglesUniversitiesKentuckyBasePathologicNerve DegenerationDiagnosisElderlyAgingHippocampal Sclerosis
Grant awards (60)
Federated digital pathology platform for AD/ADRD research and diagnostics$3,082,904
U24 · FY2025 · NS · contact PI
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArTâÂÂHS)$659,649
R01 · FY2025 · AG
Project 4 - Astrocytic KATP channels in LATE+HS$610,604
P01 · FY2025 · AG · contact PI
Core C - Human Consultation-Biosamples-Biomarkers Core$402,451
P01 · FY2025 · AG · contact PI
Core D: University of Kentucky Alzheimer's Disease Core Center$273,211
P30 · FY2025 · AG · contact PI
Age-related TDP-43 neuropathology: using disease-driving mechanisms to guide classification$790,914
R01 · FY2024 · NS
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArTâÂÂHS)$703,505
R01 · FY2024 · AG
Project 4 - Astrocytic KATP channels in LATE+HS$604,813
P01 · FY2024 · AG · contact PI
Core C - Human Consultation-Biosamples-Biomarkers Core$414,511
P01 · FY2024 · AG · contact PI
Core D: University of Kentucky Alzheimer's Disease Core Center$277,034
P30 · FY2024 · AG · contact PI
Federated digital pathology platform for AD/ADRD research and diagnostics$1,778,991
U24 · FY2023 · NS · contact PI
Genetic Architecture of Aging-Related TDP-43 and Mixed Pathology Dementia$1,714,473
RF1 · FY2023 · AG
Project 4 - Astrocytic KATP channels in LATE+HS$609,403
P01 · FY2023 · AG · contact PI
Core C - Human Consultation-Biosamples-Biomarkers Core$414,511
P01 · FY2023 · AG · contact PI
Core D: University of Kentucky Alzheimer's Disease Core Center$280,700
P30 · FY2023 · AG · contact PI
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArTâÂÂHS)$716,551
R01 · FY2022 · AG
Project 4 - Astrocytic KATP channels in LATE+HS$622,653
P01 · FY2022 · AG · contact PI
Core C - Human Consultation-Biosamples-Biomarkers Core$414,511
P01 · FY2022 · AG · contact PI
Core D: University of Kentucky Alzheimer's Disease Core Center$280,137
P30 · FY2022 · AG · contact PI
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging$740,936
R01 · FY2021 · AG
Novel pathogenetic mechanism for hippocampal sclerosis, a common Alzheimers mimic$427,191
R01 · FY2021 · AG · contact PI
Core D: University of Kentucky Alzheimer's Disease Core Center$285,735
P30 · FY2021 · AG · contact PI
Age-related TDP-43 neuropathology: using disease-driving mechanisms to guide classification$3,179,031
RF1 · FY2020 · NS
Novel pathogenetic mechanism for hippocampal sclerosis, a common Alzheimers mimic$434,093
R01 · FY2020 · AG · contact PI
Core D: Neuropathology Core$267,305
P30 · FY2020 · AG · contact PI
Novel misfolded proteins in ADRD: proteomics, genetics, and clinical-pathological correlations$191,250
R21 · FY2020 · AG · contact PI
Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArTâÂÂHS)$763,006
R01 · FY2019 · AG
Novel pathogenetic mechanism for hippocampal sclerosis, a common Alzheimers mimic$442,202
R01 · FY2019 · AG · contact PI
Core D: Neuropathology Core$267,305
P30 · FY2019 · AG · contact PI
Novel misfolded proteins in ADRD: proteomics, genetics, and clinical-pathological correlations$229,500
R21 · FY2019 · AG · contact PI
Novel pathogenetic mechanism for hippocampal sclerosis, a common Alzheimers mimic$451,688
R01 · FY2018 · AG · contact PI
Core D: Neuropathology Core$267,305
P30 · FY2018 · AG · contact PI
Novel pathogenetic mechanism for hippocampal sclerosis, a common Alzheimers mimic$458,573
R01 · FY2017 · AG · contact PI
CELLULAR CHANGES ALTERING SYNAPTIC CONNECTIVITY IN PRECLINICAL AD$308,525
R01 · FY2017 · AG · contact PI
Core D: Neuropathology Core$267,305
P30 · FY2017 · AG · contact PI
Testing a therapeutic strategy for hippocampal sclerosis of aging, a key AD mimic$188,125
R21 · FY2017 · AG · contact PI
Modulation of microRNA pathways by gemfibrozil in predementia Alzheimer disease$537,355
R01 · FY2016 · AG
CELLULAR CHANGES ALTERING SYNAPTIC CONNECTIVITY IN PRECLINICAL AD$308,525
R01 · FY2016 · AG · contact PI
Core D: Neuropathology Core$267,305
P30 · FY2016 · AG · contact PI
Testing a therapeutic strategy for hippocampal sclerosis of aging, a key AD mimic$225,750
R21 · FY2016 · AG · contact PI
Modulation of microRNA pathways by gemfibrozil in predementia Alzheimer disease$44,229
R01 · FY2015 · AG
Modulation of microRNA pathways by gemfibrozil in predementia Alzheimer disease$499,395
R01 · FY2014 · AG
Sexually dimorphic miR-497 regulates alpha-synuclein and alpha-synucleinopathy$185,625
R21 · FY2014 · NS · contact PI
Modulation of microRNA pathways by gemfibrozil in predementia Alzheimer disease$486,839
R01 · FY2013 · AG
Sexually dimorphic miR-497 regulates alpha-synuclein and alpha-synucleinopathy$225,000
R21 · FY2013 · NS · contact PI
MiR-15/107 microRNAs are important genetic regulators in Alzheimer disease$371,250
R56 · FY2012 · NS · contact PI
A specific microRNA (Mir-107) is a potential therapeutic target in Alzheimer's di$314,059
R01 · FY2011 · NS · contact PI
Aperio ScanScope XT Digital Slide Scanner System$283,657
S10 · FY2011 · RR · contact PI
Novel assay identifies all microRNA targets in Alzheimer and normal aged brains$151,660
R21 · FY2011 · AG · contact PI
A specific microRNA (Mir-107) is a potential therapeutic target in Alzheimer's di$317,265
R01 · FY2010 · NS · contact PI
Novel assay identifies all microRNA targets in Alzheimer and normal aged brains$189,338
R21 · FY2010 · AG · contact PI
A specific microRNA (Mir-107) is a potential therapeutic target in Alzheimer's di$320,469
R01 · FY2009 · NS · contact PI
Alpha-synuclein mRNA is a putative microRNA target$176,729
K08 · FY2009 · NS · contact PI
GENOMIC AND PROTEOMIC DETERMINANTS OF LOWER EXTREMITY REVASCULARIZATION FAILURE$13,001
M01 · FY2009 · RR · contact PI
A specific microRNA (Mir-107) is a potential therapeutic target in Alzheimer's di$320,469
R01 · FY2008 · NS · contact PI
Alpha-synuclein mRNA is a putative microRNA target$176,729
K08 · FY2008 · NS · contact PI
Alpha-synuclein mRNA is a putative microRNA target$175,018
K08 · FY2007 · NS · contact PI
Alpha-synuclein mRNA is a putative microRNA target$162,000
K08 · FY2006 · NS · contact PI
Alpha-synuclein mRNA is a putative microRNA target$109,755
K08 · FY2005 · NS
Alpha-synuclein mRNA is a putative microRNA target$62,373
K08 · FY2005 · NS